Sweden· SE-20110602000163
Jakavi 5 mg Tablett
A medicinal product containing ruxolitinib, registered in Sweden by Novartis Europharm Limited.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Ruxolitinib
- Manufacturer
- Novartis Europharm Limited
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20110602000163
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ruxolitinib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJAKAVINovartis Europharm Limited, Dublin
- NetherlandsJakavi 5 mg, tabletNovartis Europharm Limited
- FinlandJakaviParanova Oy
- SwitzerlandJakavi
- IcelandJakaviNovartis Europharm Limited*
- SpainJAKAVI 5 MG COMPRIMIDOSNovartis Europharm Limited
- United StatesJAKAFIIncyte Corporation
- NorwayJakaviNovartis Europharm Limited (1)
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Polink, Ruxib
- Bulgaria · Руджави, Руксолитиниб Сандоз
- Cyprus · Ruxolitinib Sandoz
- Czechia · Ruxolitinib Msn, Ruxolitinib Sandoz
- Denmark · Ruxolitinib "sandoz", Ruxolitinib Devatis
- Estonia · Ruxolitinib Msn
- Spain · Ruxolitinib Cipla, Ruxolitinib Vivanta
- Finland · Ruxolitinib Orion
- France · Ruxolitinib Biogaran, Ruxolitinib Olpha
- United Kingdom (Northern Ireland) · Ruxolitinib Msn Laboratories Europe, Ruxolitinib Torrent
- Greece · Jakulya
- Croatia · Ruksolitinib Devatis, Ruksolitinib Msn
- Hungary · Ruxolitinib Sandoz
- Iceland · Jakavi, Jakulya
- Italy · Ruxolitinib Vivanta
- Liechtenstein · Jakavi, Opzelura
- Lithuania · Ruxolitinib Msn, Ruxolitinib Olpha
- Latvia · Ruxolitinib Msn
- Malta · Donlize, Ruxolitinib Medichem
- Netherlands · Ruxolitinib Accord, Ruxolitinib Advanz Pharma
- Norway · Jakavi, Opzelura
- Romania · Ruxolitinib Msn
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/74d89493-9aba-4a4a-a5da-893837907767 GET /v1/drugs/74d89493-9aba-4a4a-a5da-893837907767?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EMA",
"EPAR"
],
"se_npl_id": "20110602000163",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20110602000163",
"product_doc_link": "https://www.ema.europa.eu/en/medicines/human/EPAR/jakavi"
}See everything about ruxolitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.